MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLTNYSE / NASDAQHealthcareSmall cap

$5.94-$0.48 (-7.5%)

Last close · Data as of Nov 20, 2026

Market cap
$1.4B
Revenue
$0.00
ROCE
-36.9%

This period includes a one-day price step on 27 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

MapLight Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-27.9%
3M
-47.1%
6M
Hidden
1Y
Hidden
5Y
Short history
  • This period includes a one-day price step on 27 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
  • A period is left blank when the price history is shorter than the period.

52-week range

This period includes a one-day price step on 27 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.48 (-7.5%) from $6.42 to $5.94 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MPLT, bought on each weekday since 2025.

News & filings

What MapLight Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 161 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.
  • This period includes a one-day price step on 27 Jul 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.

Read moreShow less

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Sector
Healthcare
Shares outstanding
44.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.4B
P/B
3.0x
52-week high
Hidden
52-week low
Hidden

Profitability

ROE
-35.2%
ROCE
-36.9%
ROIC
-32.0%
ROA
-33.6%

Growth

Revenue
$0.00
Free cash flow
-$138.6M

Solvency

Current ratio
20.00
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.86
Cash / Market cap
22.4%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

MapLight Therapeutics, Inc. revenue and net profit by fiscal year
MapLight Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2025$0.00-$161.2M

Cash flows

FY2025: -$138.1M from operations, -$138.6M free after investment (dashed).

MapLight Therapeutics, Inc. operating and free cash flow by fiscal year
MapLight Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2025-$138.1M-$138.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$168.5M
Net profit
-$161.2M
Cash from operations
-$138.1M
Free cash flow
-$138.6M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$168.5M-$161.2M-$138.6M-35.2%——

Monthly returns

Month-by-month returns of MPLT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$479.5M
Liabilities$21.1M
Equity$458.4M
Paid-in capital$819.1M
Retained earnings-$360.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MPLT highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

Not shown (no positive earnings and no EV / Sales): MapLight Therapeutics, Inc., Bicara Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
MapLight Therapeutics, Inc.MPLTthis company$1.4B—3.0x-35.2%—
AtriCure, Inc.ATRC$1.4B-120.6x2.8x-2.3%79.2x
Precigen, Inc.PGEN$1.4B-5.5x65.8x-1198.6%-5.9x
Integra LifeSciences Holdings CorporationIART$1.4B-2.6x1.3x-49.5%-9.7x
Butterfly Network, Inc.BFLY$1.4B—6.9x-39.3%—
UroGen Pharma Ltd.URGN$1.3B-8.8x-12.7x145.5%-10.0x
Bicara Therapeutics Inc.BCAX$1.3B-9.7x3.3x-34.4%-8.0x
Inhibrx Biosciences, Inc.INBX$1.3B-9.6x167.5x-1752.2%-10.5x
Ardelyx, Inc.ARDX$1.3B-21.7x8.0x-36.9%-50.5x
Peer median—-9.6x5.1x-38.1%-9.7x

Year-to-date ROI

MPLT since 1 January, against earlier years.

Historical volatility

MPLT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$169.1M
Research and developmentResearch And Development$138.3M
Total expensesTotal Expenses$169.1M
Pretax incomePretax Income-$161.2M

Learn while you research

Academy chapters picked for MapLight Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →